Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. Larbouret C, et al. Among authors: chardes t. Neoplasia. 2012 Feb;14(2):121-30. doi: 10.1593/neo.111602. Neoplasia. 2012. PMID: 22431920 Free PMC article.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Among authors: chardes t. Cancer Immunol Immunother. 2010 Sep;59(9):1295-312. doi: 10.1007/s00262-010-0869-2. Epub 2010 Jun 8. Cancer Immunol Immunother. 2010. PMID: 20532501 Free PMC article. Review.
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardès T, Poul MA, Mathis G, Bazin H, Pèlegrin A. Gaborit N, et al. Among authors: chardes t. J Biol Chem. 2011 Apr 1;286(13):11337-45. doi: 10.1074/jbc.M111.223503. Epub 2011 Jan 31. J Biol Chem. 2011. PMID: 21282108 Free PMC article.
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Among authors: chardes t. Breast Cancer Res. 2011 Feb 4;13(1):R17. doi: 10.1186/bcr2826. Breast Cancer Res. 2011. PMID: 21294885 Free PMC article.
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Lazrek Y, et al. Among authors: chardes t. Neoplasia. 2013 Mar;15(3):335-47. doi: 10.1593/neo.121960. Neoplasia. 2013. PMID: 23479511 Free PMC article.
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. Thomas G, et al. Among authors: chardes t. Oncotarget. 2014 Aug 30;5(16):7138-48. doi: 10.18632/oncotarget.2231. Oncotarget. 2014. PMID: 25216528 Free PMC article.
74 results